Related Experiment Videos
Financial evaluation of value-creating biosimilar development candidates: a business case study of low-, medium- and
1Research and Development, Intas Pharmaceuticals Ltd. (Biopharma Division), Ahmedabad, India.
Background:
Selection of a biosimilar development candidate requires detailed and careful analysis to ensure value creation.
Research Design And Methods:
We applied the net present value (NPV) model for financial evaluation of biosimilar development candidates for the global market. Biosimilar development candidates from three categories were identified based on the global sales of their respective original biological products (OBPs): >$1 and ≤$4 billion, >$4 and ≤$7 billion and >$7 and ≤$10 billion. The standard NPV and risk-adjusted NPV (rNPV) were calculated under the base-case and various scenarios related to development costs, sales, selling, general and administrative expense, cost of goods sold, and discount rates.
Results:
A biosimilar to an OBP with sales of $1.6 billion has some financial risk. Biosimilars to OBPs with sales of $5.5 billion and $9.4 billion have very less financial risk under the base-case scenario of analysis. Sales of an OBP had impact on the financial valuation and attractiveness of a biosimilar. Sensitivity of rNPV to different parameters varied for three biosimilars. Discount rates, sales and development costs were important parameters affecting financial valuation of biosimilars.
Conclusion:
Biosimilar development candidate selection requires a thorough financial evaluation considering product-, company- and market-specific aspects.